DK3205661T3 - Hsp70-afledt immunitetsinducerende peptid - Google Patents

Hsp70-afledt immunitetsinducerende peptid Download PDF

Info

Publication number
DK3205661T3
DK3205661T3 DK15849707.3T DK15849707T DK3205661T3 DK 3205661 T3 DK3205661 T3 DK 3205661T3 DK 15849707 T DK15849707 T DK 15849707T DK 3205661 T3 DK3205661 T3 DK 3205661T3
Authority
DK
Denmark
Prior art keywords
peptime
hsp70
inducing
derived immunity
immunity
Prior art date
Application number
DK15849707.3T
Other languages
English (en)
Inventor
Tomoya Miyakawa
Masaaki Oka
Shoichi Hazama
Koji Tamada
Keiko Udaka
Original Assignee
Cytlimic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytlimic Inc filed Critical Cytlimic Inc
Application granted granted Critical
Publication of DK3205661T3 publication Critical patent/DK3205661T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464476—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/53—Liver

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15849707.3T 2014-10-07 2015-10-07 Hsp70-afledt immunitetsinducerende peptid DK3205661T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014206730 2014-10-07
PCT/JP2015/078504 WO2016056596A1 (ja) 2014-10-07 2015-10-07 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法

Publications (1)

Publication Number Publication Date
DK3205661T3 true DK3205661T3 (da) 2021-08-02

Family

ID=55653202

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15849707.3T DK3205661T3 (da) 2014-10-07 2015-10-07 Hsp70-afledt immunitetsinducerende peptid

Country Status (12)

Country Link
US (3) US10537626B2 (da)
EP (2) EP3925968A3 (da)
JP (1) JP6423889B2 (da)
CN (1) CN107001418A (da)
AU (2) AU2015329070B2 (da)
BR (1) BR112017006969A2 (da)
CA (2) CA3116265A1 (da)
DK (1) DK3205661T3 (da)
ES (1) ES2882827T3 (da)
RU (1) RU2684911C2 (da)
TW (1) TWI687434B (da)
WO (1) WO2016056596A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
CN107428815B (zh) 2015-03-09 2021-07-09 Cytlimic公司 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
ES2844049T3 (es) 2015-04-07 2021-07-21 Cytlimic Inc Adyuvante para vacunas contra el cáncer
RU2759728C2 (ru) * 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
WO2023163094A1 (ja) * 2022-02-25 2023-08-31 日本電気株式会社 成人ｔ細胞白血病の治療又は予防のための医薬組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) * 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO2002022656A2 (en) * 2000-09-13 2002-03-21 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
US20030171280A1 (en) * 2001-07-31 2003-09-11 Soderstrom Karl Petter Compositions and methods for modulation of immune responses
AU2003254950A1 (en) 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JPWO2006004182A1 (ja) 2004-07-07 2008-04-24 日本電気株式会社 配列予測システム
WO2006123155A2 (en) 2005-05-19 2006-11-23 Glaxosmithkline Biologicals S.A. Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant
CN101313063B (zh) 2005-08-09 2013-04-03 肿瘤疗法·科学股份有限公司 用于hla-a2阳性人群的来自磷脂酰肌醇蛋白聚糖-3(gpc3)的癌症排斥抗原肽以及含有该肽的药物
JPWO2007119515A1 (ja) 2006-03-28 2009-08-27 昇志 佐藤 新規腫瘍抗原ペプチド
RU2333767C2 (ru) * 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
SG175566A1 (en) 2006-10-17 2011-11-28 Oncotherapy Science Inc Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
WO2008106491A2 (en) * 2007-02-27 2008-09-04 University Of Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
JP2010532785A (ja) * 2007-07-06 2010-10-14 ウニベルジテイト・ウトレヒト・ホールディング・ビー．ブイ． 炎症性疾患および自己免疫疾患の治療および予防
EP2195333A1 (en) 2007-09-12 2010-06-16 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
EP2486134B1 (en) 2009-10-06 2014-01-08 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
IN2014MN01513A (da) * 2012-02-07 2015-09-11 Jolla Inst Allergy Immunolog
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
CN103897047B (zh) * 2012-12-27 2016-01-20 中国科学院植物研究所 蛋白BhHSP70-1及其编码基因与应用
HUE044430T2 (hu) 2013-03-01 2019-10-28 Astex Pharmaceuticals Inc Gyógyszerkombinációk
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
BR112017006969A2 (pt) 2014-10-07 2017-12-19 Cytlimic Inc peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
CN107428815B (zh) 2015-03-09 2021-07-09 Cytlimic公司 源于gpc3的肽、使用其的用于治疗或预防癌症的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
ES2844049T3 (es) 2015-04-07 2021-07-21 Cytlimic Inc Adyuvante para vacunas contra el cáncer

Also Published As

Publication number Publication date
US20200121772A1 (en) 2020-04-23
EP3925968A2 (en) 2021-12-22
CA2963909C (en) 2021-06-15
EP3205661A1 (en) 2017-08-16
EP3205661A4 (en) 2018-08-08
CA2963909A1 (en) 2016-04-14
AU2015329070A1 (en) 2017-04-27
CA3116265A1 (en) 2016-04-14
RU2017115719A3 (da) 2018-11-14
TW201619190A (zh) 2016-06-01
WO2016056596A1 (ja) 2016-04-14
JP6423889B2 (ja) 2018-11-14
RU2684911C2 (ru) 2019-04-16
AU2018274976A1 (en) 2019-01-03
BR112017006969A2 (pt) 2017-12-19
AU2018274976B2 (en) 2019-05-02
US20220193213A1 (en) 2022-06-23
EP3925968A3 (en) 2022-03-02
US20180169199A1 (en) 2018-06-21
AU2015329070B2 (en) 2018-11-22
ES2882827T3 (es) 2021-12-02
RU2017115719A (ru) 2018-11-14
US10537626B2 (en) 2020-01-21
JPWO2016056596A1 (ja) 2017-08-17
CN107001418A (zh) 2017-08-01
US11304997B2 (en) 2022-04-19
EP3205661B1 (en) 2021-07-07
TWI687434B (zh) 2020-03-11

Similar Documents

Publication Publication Date Title
DK3209778T3 (da) Kombination
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
DK3006072T3 (da) Karadgang
DE112015001664A5 (de) Betätigungsaktuator
DK3183340T3 (da) Termolabile exonukleaser
FR3024324B3 (fr) Souffleur
DK3122763T3 (da) Antimikrobielle peptiddendrimerer
DK3110439T3 (da) Pcsk9-vacciner
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3205661T3 (da) Hsp70-afledt immunitetsinducerende peptid
DE112015005041A5 (de) Gargerätevorrichtung
DE102014000623A8 (de) Halbhohlnietelement
DK3009858T3 (da) Skyradar
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer
ES1133830Y (es) Columbario
DK3091875T3 (da) Vipbar taburet
DE112015005055A5 (de) Gargerätevorrichtung
DK3191825T3 (da) Kreatininbiosensor
ES1137381Y (es) Trompo
ES1136185Y (es) Huevera